Long‐Term Efficacy and Safety of Protease Inhibitor Switching to Nevirapine in HIV‐Infected Patients with Undetectable Virus LoadPaloma Gil, Manuel Fernández Guerrero, Miguel Górgolas et al.|Clinical Infectious Diseases|2004Cited by 28
Peripheral T follicular helper Cells Make a Difference in HIV Reservoir Size between Elite Controllers and Patients on Successful cARTMarcial García, Norma Rallón, Miguel Górgolas et al.|Scientific Reports|2017Cited by 28
Circulating immune complexes from HIV‐1<sup>+</sup> patients induces apoptosis on‘qc normal lymphocytesEsther Aceituno, R. García, Susana Castañón et al.|Immunology|1997Cited by 17
Refrain from Telling Bad News: Patients with Leishmaniasis Can Have False-Positive HIV Test ResultsAntonio J. Salinas, Manuel Fernández Guerrero, Miguel Górgolas|Clinical Infectious Diseases|2007Cited by 16
A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral loadJA Arranz Caso, Miguel Górgolas, JC López et al.|HIV Medicine|2005Cited by 14